A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy

Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis

(2017) Yingying Chen et al.   HUMAN PATHOLOGY

DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain

(2017) Samira Abu Jhaisha et al.   Scientific Reports

Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells

(2016) Zhen Li et al.   CANCER LETTERS

To wake up cancer stem cells, or to let them sleep, that is the question

(2016) Shoichiro Takeishi et al.   CANCER SCIENCE

A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy

(2016) James MacDonald et al.   MOLECULAR CANCER RESEARCH

DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway

(2016) Rajeev Singh et al.   Oncotarget

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

(2016) Wolfgang Gruber et al.   Oncotarget

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

(2016) Arnaud Duchon et al.   Frontiers in Behavioral Neuroscience

The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2

(2016) Florian Glenewinkel et al.   Scientific Reports

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome

(2015) Anne L. Ashford et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

DYRK protein kinases

(2015) Ulf Soppa et al.   CURRENT BIOLOGY

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

(2015) Benjamin J. Thompson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis

(2015) Jason G. Kettle et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase

(2015) L.-N. Song et al.   MOLECULAR CANCER RESEARCH

Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1

(2015) Philipp Schneider et al.   Nature Communications

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer

(2015) Jangsoon Lee et al.   Journal of Cancer

Mirk/dyrk1B kinase is upregulated following inhibition of mTOR

(2014) Xiaobing Deng et al.   CARCINOGENESIS

The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

(2014) Ulf Soppa et al.   CELL CYCLE

A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B

(2014) Ali R. Keramati et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors

(2014) Christian Schmitt et al.   PLoS One

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288

(2013) Anne L. Ashford et al.   BIOCHEMICAL JOURNAL

Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells

(2013) Jingchun Gao et al.   Cancer Cell International

The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis

(2013) S. Boichuk et al.   CANCER RESEARCH

Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

(2013) Lin Tang et al.   CELL CYCLE

Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle

(2013) Jia-Yun Chen et al.   MOLECULAR CELL

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control

(2012) Walter Becker   CELL CYCLE

Staying alive

(2012) James R. Valcourt et al.   CELL CYCLE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice

(2012) T. Masuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

(2011) L. Litovchick et al.   GENES & DEVELOPMENT

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

(2011) D. Z. Ewton et al.   MOLECULAR CANCER THERAPEUTICS

Dyrk1a activates antioxidant NQO1 expression through an ERK1/2–Nrf2 dependent mechanism

(2011) Christophe Noll et al.   MOLECULAR GENETICS AND METABOLISM

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

(2010) Jingchun Gao et al.   CANCER BIOLOGY & THERAPY

DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles

(2010) Sergi Aranda et al.   FASEB JOURNAL

Activation, regulation, and inhibition of DYRK1A

(2010) Walter Becker et al.   FEBS Journal

Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2

(2010) Jing Hu et al.   INTERNATIONAL JOURNAL OF CANCER

Dyrk1A Overexpression Inhibits Proliferation and Induces Premature Neuronal Differentiation of Neural Progenitor Cells

(2010) O. Yabut et al.   JOURNAL OF NEUROSCIENCE

DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS

(2010) Matthias Lauth et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer

(2010) Eileen Friedman   Cancers

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

(2009) X. Deng et al.   CANCER RESEARCH

The kinase Mirk is a potential therapeutic target in osteosarcoma

(2009) C. Yang et al.   CARCINOGENESIS

Mirk Regulates the Exit of Colon Cancer Cells from Quiescence

(2009) Kideok Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

FOXOs, cancer and regulation of apoptosis

(2008) Z Fu et al.   ONCOGENE